Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Spectrum Pharmaceuticals, Inc. : Hagens Berman Reminds Spectrum Pharmaceuticals Investors of May 13, 2013, Deadline in Securities Lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/03/2013 | 03:35pm CEST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) investors of the May 13, 2013, lead plaintiff deadline in a pending lawsuit filed on their behalf. Investors who suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing SPPI@hbsslaw.com.

The lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Investors who wish to move to be a lead plaintiff in the case may also contact the firm by calling (510) 725-3000 and must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357
Mark@firmani.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPECTRUM PHARMACEUTICALS,
03/14 SPECTRUM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
03/10 SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8..
03/08 SPECTRUM PHARMACEUTICALS : Pharma reports 4Q loss
03/08 SPECTRUM PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
03/08 SPECTRUM PHARMACEUTICALS : Reports Fourth Quarter 2016 and Full Year 2016 Financ..
03/01 SPECTRUM PHARMACEUTICALS : Announces Fourth Quarter and Full Year 2016 Financial..
02/16 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the 2017 RBC Capital M..
01/09 SPECTRUM PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements an..
2016 SPECTRUM PHARMACEUTICALS : Research Reports Initiation on Biotech Stocks -- Incy..
2016 SPECTRUM PHARMACEUTICALS : Highlights Promising Preclinical Data Evaluating Pozi..
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/09 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
03/08 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q4 2016 Results - Ea..
03/08 After Hours Gainers / Losers
03/08 Spectrum Pharma Q4 top line down 30%, net loss widens; shares down 15% after ..
03/08 Spectrum Pharmaceuticals beats by $0.03, beats on revenue
Advertisement
Financials ($)
Sales 2017 125 M
EBIT 2017 -64,3 M
Net income 2017 -68,0 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 4,23x
Capi. / Sales 2018 4,07x
Capitalization 530 M
More Financials
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 9,63 $
Spread / Average Target 46%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph W. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Luigi Lenaz Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICA..49.21%530
INCYTE CORPORATION39.26%28 461
QUINTILES IMS HOLDINGS..2.55%18 400
LONZA GROUP AG3.40%10 646
CELLTRION, INC.--.--%9 851
SEATTLE GENETICS, INC.20.69%9 075
More Results